Literature DB >> 3477567

Detection and titration of neutralizing antibodies to HIV using an inhibition of the cytopathic effect of the virus on MT4 cells.

F Rey1, F Barré-Sinoussi, H Schmidtmayerova, J C Chermann.   

Abstract

An assay for determining neutralizing antibodies in sera from individuals infected with HIV was developed. This assay is based on an inhibition of the cytopathic effect observed after HIV superinfection of the HTLV-1-positive cell-line MT4. Only about 10% of asymptomatic seropositive donors exhibit a high titre over 1/500 up to 1/2000 while in 60% of sera, neutralizing antibodies were not detected. The assay reported here can also be used for the comparison of the biological properties of the different strains of HIV.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3477567     DOI： 10.1016/0166-0934(87)90008-5

Source DB:  PubMed          Journal:  J Virol Methods        ISSN： 0166-0934            Impact factor:   2.014


  14 in total

Review 1.  Role of Marine Natural Products in the Genesis of Antiviral Agents.

Authors:  Vedanjali Gogineni; Raymond F Schinazi; Mark T Hamann
Journal:  Chem Rev       Date:  2015-08-28       Impact factor: 60.622

2.  Structural variability of env and gag gene products from a highly cytopathic strain of HIV-1.

Authors:  N Yahi; J Fantini; I Hirsch; J C Chermann
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

3.  A simple assay based on HIV infection preventing the reclustering of MT-4 cells.

Authors:  G Szucs; J L Melnick; F B Hollinger
Journal:  Bull World Health Organ       Date:  1988       Impact factor: 9.408

4.  Development of an enzyme-linked immunosorbent spot assay to measure serum-neutralizing antibodies against coxsackievirus B3.

Authors:  Lisheng Yang; Delei He; Min Tang; Zhiqun Li; Che Liu; Longfa Xu; Yixin Chen; Hailian Du; Qinjian Zhao; Jun Zhang; Tong Cheng; Ningshao Xia
Journal:  Clin Vaccine Immunol       Date:  2014-01-03

5.  Agreement study between two laboratories of immunofluorescence as a confirmatory test for human immunodeficiency virus type 1 antibody screening.

Authors:  J Mahony; K Rosenthal; M Chernesky; S Castriciano; E Scheid; M Blajchman; D Harnish
Journal:  J Clin Microbiol       Date:  1989-06       Impact factor: 5.948

6.  The human immunodeficiency virus (HIV) gag gene product p18 is responsible for enhanced fusogenicity and host range tropism of the highly cytopathic HIV-1-NDK strain.

Authors:  J de Mareuil; B Brichacek; D Salaun; J C Chermann; I Hirsch
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

7.  Heterocyclic compounds that inhibit Rev-RRE function and human immunodeficiency virus type 1 replication.

Authors:  Deidra Shuck-Lee; Fei Fei Chen; Ryan Willard; Sharmila Raman; Roger Ptak; Marie-Louise Hammarskjold; David Rekosh
Journal:  Antimicrob Agents Chemother       Date:  2008-07-14       Impact factor: 5.191

8.  Synthesis and base-pairing properties of the nuclease-resistant alpha-anomeric dodecaribonucleotide alpha-[r(UCUUAACCCACA)].

Authors:  F Debart; B Rayner; G Degols; J L Imbach
Journal:  Nucleic Acids Res       Date:  1992-03-25       Impact factor: 16.971

9.  Failure of a human immunodeficiency virus (HIV) immune globulin to protect chimpanzees against experimental challenge with HIV.

Authors:  A M Prince; B Horowitz; L Baker; R W Shulman; H Ralph; J Valinsky; A Cundell; B Brotman; W Boehle; F Rey
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

10.  Attenuated Mengo virus as a vector for immunogenic human immunodeficiency virus type 1 glycoprotein 120.

Authors:  R Altmeyer; N Escriou; M Girard; A Palmenberg; S van der Werf
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.